Provider Briefing: Alphagan (Brimonidine Tartrate) Availability in 2026

As ophthalmologists, optometrists, and primary care providers, you've likely fielded patient calls about difficulty filling Alphagan P (Brimonidine tartrate) prescriptions. While the drug is not currently listed on the FDA's shortage database, intermittent availability issues at the pharmacy level continue to affect patient access and adherence.

This briefing covers the current supply landscape, prescribing considerations, cost and access factors, and tools you can leverage to help your patients stay on therapy.

Supply Timeline and Current Status

Brimonidine tartrate ophthalmic solution has not been subject to a formal FDA-listed shortage. However, intermittent stock-outs at individual pharmacy locations have been reported throughout 2025 and into early 2026. The primary drivers include:

• Distributor allocation practices: Wholesalers periodically limit order quantities for lower-volume ophthalmic products, particularly for pharmacies with inconsistent ordering patterns.
• Generic manufacturer variability: While multiple ANDA holders produce generic Brimonidine (0.15% and 0.2%), individual manufacturers have experienced production timeline shifts, creating temporary supply gaps in some distribution channels.
• Formulary-driven demand concentration: Payer formularies that preferentially cover specific concentrations (0.1%, 0.15%, or 0.2%) or specific manufacturers can create localized demand surges for those particular products.

It is important to distinguish between a true supply shortage — where insufficient product is being manufactured nationally — and the distribution fragmentation that characterizes the current Brimonidine landscape. The drug is being produced; it's the last-mile availability that varies.

Prescribing Implications

For providers managing patients on Brimonidine, the availability picture has several practical implications:

Formulation Flexibility

Alphagan P is available in 0.1% and 0.15% concentrations. The original Alphagan formulation (0.2%) is largely superseded but generic 0.2% Brimonidine remains available. When writing prescriptions, consider specifying "Brimonidine tartrate ophthalmic" with allowable substitution rather than a specific brand or concentration, where clinically appropriate. This gives pharmacies maximum flexibility to fill with whatever product they have in stock.

Generic Substitution

Generic Brimonidine is rated therapeutically equivalent (AB-rated) to Alphagan P by the FDA. For the vast majority of patients, generic substitution is clinically appropriate and significantly improves both cost and availability. The Alphagan P formulation uses Purite (stabilized oxychloro complex) as a preservative instead of benzalkonium chloride (BAK), which may matter for patients with preservative sensitivity or those on multiple preserved drops.

Adherence Risk

Brimonidine's three-times-daily dosing already makes adherence challenging compared to once-daily prostaglandin analogs. Adding availability barriers on top of a demanding regimen creates real risk of treatment gaps. If a patient reports repeated difficulty filling their prescription, consider whether a therapeutic switch is warranted — not just for convenience, but to protect against disease progression from intermittent non-adherence.

Availability Picture by Setting

Understanding where patients are most and least likely to encounter availability issues can help you guide them proactively:

• Large chain pharmacies: Generally reliable for generic Brimonidine, but may be subject to corporate-level allocation limits. Brand Alphagan P is less consistently stocked.
• Independent pharmacies: Often have access to multiple wholesalers and can sometimes source products that chain pharmacies cannot. Worth recommending to patients having difficulty.
• Mail-order/specialty pharmacies: Typically maintain broader inventory for maintenance medications. A good option for patients with stable prescriptions who benefit from 90-day supplies.
• Hospital outpatient pharmacies: Usually stock Brimonidine consistently as part of their ophthalmology formulary.

Cost and Access Considerations

Cost remains a significant factor in Brimonidine access:

• Brand Alphagan P (5 mL): $150-$270 cash price. Covered by many commercial plans, but may require prior authorization.
• Generic Brimonidine (5 mL): $9-$50 with discount coupons (GoodRx, SingleCare); $32-$153 without coupons.
• AbbVie co-pay savings: The manufacturer offers up to $2,160/year in co-pay assistance for commercially insured patients through the "At Your Service" program (savewithays.com).
• Patient assistance: AbbVie's Patient Assistance Foundation provides Alphagan P at no cost to qualifying uninsured or underinsured patients.
• Medicare Part D: Generic Brimonidine is typically covered on preferred generic tiers with low copays ($0-$15).

When cost drives patients toward brand avoidance but the generic is temporarily unavailable at their pharmacy, the result can be a treatment gap. Proactively discussing cost-saving strategies with patients can help prevent this.

Tools and Resources for Your Practice

Several tools can help streamline medication access for your glaucoma patients:

• Medfinder for Providers: Helps your team and your patients locate pharmacies with Alphagan or Brimonidine in stock. Consider integrating this into your discharge workflow for patients starting or changing glaucoma therapy.
• AbbVie At Your Service (savewithays.com): For patients on brand Alphagan P, this co-pay program can significantly reduce out-of-pocket costs.
• Prior authorization support: If payers require step therapy or PA, document the clinical rationale thoroughly. Common acceptable justifications include prior prostaglandin intolerance, contraindications to beta-blockers, or the need for adjunctive therapy.

Alternative Agents to Consider

When Brimonidine is unavailable or clinically suboptimal, consider these therapeutic alternatives:

• Latanoprost (Xalatan) / Travoprost (Travatan Z): Prostaglandin analogs. Once-daily dosing, strong IOP reduction (25-30%), widely available generics ($5-$15). First-line for most open-angle glaucoma patients.
• Timolol (Timoptic): Beta-blocker. Well-established efficacy, very affordable generic (<$10). Contraindicated in asthma, COPD, bradycardia.
• Dorzolamide (Trusopt): Carbonic anhydrase inhibitor. Can be combined with other agents. Avoid in sulfonamide allergy.
• Combigan (Brimonidine + Timolol): Fixed combination that may be easier to find than standalone Brimonidine and simplifies regimens for patients already on both agents.
• Simbrinza (Brimonidine + Brinzolamide): Beta-blocker-free combination option for patients with cardiovascular contraindications.
• Netarsudil (Rhopressa): ROCK inhibitor, once-daily dosing. Newer mechanism of action, though conjunctival hyperemia is common.

For a patient-facing overview of these options, see our Alphagan alternatives guide.

Looking Ahead

The Brimonidine supply landscape is expected to remain stable through 2026, with additional generic competition continuing to improve both pricing and availability. No major patent-related disruptions are anticipated for this mature molecule.

The ongoing shift toward preservative-free formulations across ophthalmic products may create incremental demand shifts, but this is unlikely to cause significant supply disruptions for traditional preserved Brimonidine formulations.

Providers should continue to monitor the FDA Drug Shortage Database and ASHP Drug Shortage List for any changes in status. For real-time pharmacy-level availability data, Medfinder for Providers remains a practical tool for your practice.

Final Thoughts

While Alphagan is not in crisis, the intermittent availability pattern is enough to disrupt care for your most vulnerable glaucoma patients. Proactive prescribing strategies — formulation flexibility, generic preference, early refill counseling, and familiarity with availability tools — can help bridge the gap between supply and patient need.

For additional resources, see our provider guide to helping patients find Alphagan in stock.